AU613009B2 - 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid - Google Patents

4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid Download PDF

Info

Publication number
AU613009B2
AU613009B2 AU11758/88A AU1175888A AU613009B2 AU 613009 B2 AU613009 B2 AU 613009B2 AU 11758/88 A AU11758/88 A AU 11758/88A AU 1175888 A AU1175888 A AU 1175888A AU 613009 B2 AU613009 B2 AU 613009B2
Authority
AU
Australia
Prior art keywords
compound
formula
subject
salt
monohydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU11758/88A
Other languages
English (en)
Other versions
AU1175888A (en
Inventor
Bernhard Aebischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of AU1175888A publication Critical patent/AU1175888A/en
Application granted granted Critical
Publication of AU613009B2 publication Critical patent/AU613009B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request to Amend Deed and Register Assignors: SANDOZ LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU11758/88A 1987-02-18 1988-02-16 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid Ceased AU613009B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8703749 1987-02-18
GB878703749A GB8703749D0 (en) 1987-02-18 1987-02-18 Piperazinecarboxylic acid

Publications (2)

Publication Number Publication Date
AU1175888A AU1175888A (en) 1988-08-25
AU613009B2 true AU613009B2 (en) 1991-07-25

Family

ID=10612501

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11758/88A Ceased AU613009B2 (en) 1987-02-18 1988-02-16 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid

Country Status (28)

Country Link
JP (1) JPH0723387B2 (enrdf_load_stackoverflow)
KR (1) KR960015190B1 (enrdf_load_stackoverflow)
AT (1) AT391320B (enrdf_load_stackoverflow)
AU (1) AU613009B2 (enrdf_load_stackoverflow)
BE (1) BE1002427A3 (enrdf_load_stackoverflow)
CA (1) CA1327799C (enrdf_load_stackoverflow)
CH (1) CH675125A5 (enrdf_load_stackoverflow)
CY (1) CY1739A (enrdf_load_stackoverflow)
DE (1) DE3804936C2 (enrdf_load_stackoverflow)
DK (1) DK168441B1 (enrdf_load_stackoverflow)
ES (2) ES2011319A6 (enrdf_load_stackoverflow)
FI (1) FI86733C (enrdf_load_stackoverflow)
FR (1) FR2610932B1 (enrdf_load_stackoverflow)
GB (2) GB8703749D0 (enrdf_load_stackoverflow)
GR (1) GR1002471B (enrdf_load_stackoverflow)
HK (1) HK142093A (enrdf_load_stackoverflow)
HU (2) HU199858B (enrdf_load_stackoverflow)
IE (1) IE59098B1 (enrdf_load_stackoverflow)
IL (1) IL85436A0 (enrdf_load_stackoverflow)
IT (1) IT1219447B (enrdf_load_stackoverflow)
LU (1) LU87129A1 (enrdf_load_stackoverflow)
MY (1) MY103206A (enrdf_load_stackoverflow)
NL (1) NL8800412A (enrdf_load_stackoverflow)
NZ (1) NZ223529A (enrdf_load_stackoverflow)
PH (1) PH25512A (enrdf_load_stackoverflow)
PT (1) PT86776B (enrdf_load_stackoverflow)
SE (1) SE467256B (enrdf_load_stackoverflow)
ZA (1) ZA881146B (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651125B2 (en) * 1990-06-18 1994-07-14 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Treatment of mood disorders with functional antagonists of the glycine/NMDA receptor complex

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU202111B (en) * 1988-03-11 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing (r)-(e)-4--(3-phosphono-2-propenyl)-2-piperazine-carboxylic acid as active component
EP0488959A3 (en) * 1990-11-28 1992-08-05 Sandoz Ltd. New uses of competitive nmda receptor antagonists
US5260286A (en) * 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
EP0826032A1 (de) * 1995-05-08 1998-03-04 Lonza Ag Biotechnologisches verfahren zur herstellung von r-alpha-piperazincarbonsäure und s-alpha-piperazincarbonsäureamid
IL132836A0 (en) 1997-05-12 2001-03-19 Ortho Mcneil Pharm Inc Arylsubstituted piperazines useful in the treatment of benign prostatic hyperplasia
GB9821179D0 (en) * 1998-09-30 1998-11-25 Merck Sharp & Dohme Therapeutic use
JP2008124531A (ja) 2006-11-08 2008-05-29 Nec Electronics Corp 半導体装置およびオーディオプロセッサチップ
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2157685A (en) * 1984-04-17 1985-10-30 Nat Res Dev Piperazine derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2157685A (en) * 1984-04-17 1985-10-30 Nat Res Dev Piperazine derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU651125B2 (en) * 1990-06-18 1994-07-14 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Treatment of mood disorders with functional antagonists of the glycine/NMDA receptor complex

Also Published As

Publication number Publication date
GR880100084A (el) 1988-12-16
PT86776B (pt) 1992-05-29
GR1002471B (el) 1996-11-15
HU199858B (en) 1990-03-28
SE8800541D0 (sv) 1988-02-17
FI880744A0 (fi) 1988-02-17
CY1739A (en) 1995-10-20
ES2021904A6 (es) 1991-11-16
FI86733C (fi) 1992-10-12
IE59098B1 (en) 1994-01-12
FI880744L (fi) 1988-08-19
PT86776A (pt) 1988-03-01
MY103206A (en) 1993-05-29
IE880413L (en) 1988-08-18
IL85436A (enrdf_load_stackoverflow) 1992-12-01
JPH0723387B2 (ja) 1995-03-15
AT391320B (de) 1990-09-25
GB8803438D0 (en) 1988-03-16
GB2201676B (en) 1991-01-02
CA1327799C (en) 1994-03-15
FR2610932B1 (fr) 1990-11-16
HU211269A9 (en) 1995-11-28
DE3804936C2 (de) 1997-02-13
ZA881146B (en) 1989-10-25
PH25512A (en) 1991-07-24
KR880009944A (ko) 1988-10-06
NZ223529A (en) 1991-02-26
IT1219447B (it) 1990-05-18
FI86733B (fi) 1992-06-30
JPS63203691A (ja) 1988-08-23
DK168441B1 (da) 1994-03-28
BE1002427A3 (fr) 1991-02-05
SE467256B (sv) 1992-06-22
IL85436A0 (en) 1988-07-31
KR960015190B1 (ko) 1996-11-01
LU87129A1 (fr) 1988-09-20
CH675125A5 (enrdf_load_stackoverflow) 1990-08-31
AU1175888A (en) 1988-08-25
DK79688D0 (da) 1988-02-16
ATA36788A (de) 1990-03-15
DE3804936A1 (de) 1988-09-01
NL8800412A (nl) 1988-09-16
GB8703749D0 (en) 1987-03-25
IT8847631A0 (it) 1988-02-12
ES2011319A6 (es) 1990-01-01
FR2610932A1 (fr) 1988-08-19
HUT49361A (en) 1989-09-28
GB2201676A (en) 1988-09-07
DK79688A (da) 1988-08-19
HK142093A (en) 1994-01-07

Similar Documents

Publication Publication Date Title
JPS593988B2 (ja) アミノ酸のオレフイン誘導体
JPH05320162A (ja) ペプチド性キヌクリジン
US6506753B2 (en) Methods of making and using N-desmethylzopiclone
JPH07223953A (ja) 中枢神経系疾患治療用薬剤組成物
EP1100508A2 (en) Pharmaceutical combination comprising a tricyclic compound and at least one of zolpidem, zopiclone and brotizolam for treating or preventing sleep disorders
WO2004037212A2 (en) Compositions comprising zopiclone derivatives and methods of making and using the same
AU613009B2 (en) 4-(3-phosphono-2-propenyl)-2- piperazinecarboxylic acid
WO1996029331A1 (de) Imidazochinazoline, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2007117544A2 (en) Carnitine conjugates of adamantanamines and neramexane derivatives as duel prodrugs for various uses
US12226381B2 (en) Composition of fused tricyclic gamma-amino acid derivatives and the preparation thereof
SK281085B6 (sk) Deriváty 2-(aminometyl)-3,4,7,9-tetrahydro-2h-pyrán[2,3]-indol- -8-ónov, farmaceutický prostriedok s ich obsahom a ich použitie
US4904670A (en) Pyridine derivatives having anxiety state or sleep thereapeutic properties
WO2006029549A1 (fr) Composes de quinuclidine a groupe ammonium quaternaire, procede d'elaboration et utilisation comme agents de blocage de l'acetycholine
EP0573548B1 (en) Neuroprotectant agents
JP3681770B2 (ja) 老年性痴呆症又はアルツハイマー病治療剤
HU191795B (en) Process for producing pyrrolizidine derivatives
GB2087889A (en) Naphthyridine derivatives
RU2173146C2 (ru) Производные полициклических алкалоидов как антагонисты nmda-рецептора
PL153236B1 (pl) Sposób wytwarzania kwasu piperazynokarboksylowego
JPH0710851A (ja) アミノアルコール誘導体及びその用途
JPH06234766A (ja) 光学活性イソインドリン誘導体
HK1075245A (en) Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired